Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31459870 | 0.89 | CRBN (0.32) | — | |
| SCHEMBL3682432 | 0.81 | — | — | |
| SCHEMBL341826 | 0.79 | ALDH1A1 (0.31) | ALDH1A1CYP2D6CYP3A4HSD17B10TSHR | |
| SCHEMBL27469585 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL29891818 | 0.78 | ALDH1A1 (0.30) | ALDH1A1HSD17B10HPGD | |
| SCHEMBL3676748 | 0.75 | ALDH1A1 (0.40) | ALDH1A1CYP2D6CYP3A4HSD17B10CYP1A2 | |
| SCHEMBL27064690 | 0.72 | CYP3A4 (0.38) | ALDH1A1CYP2D6CYP3A4HSD17B10CYP1A2 | |
| SCHEMBL16600593 | 0.72 | CYP3A4 (0.38) | ALDH1A1CYP2D6CYP3A4HSD17B10CYP1A2 | |
| SCHEMBL5427817 | 0.71 | CYP2C9 (0.35) | ALDH1A1CYP2D6CYP3A4HSD17B10CYP1A2 | |
| SCHEMBL22981778 | 0.69 | MGLL (0.34) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065916-A1 | METHOD OF MAKING IMIDAZOAZEPINONE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| EP-2211616-A1 | METHOD OF MAKING IMIDAZOAZEPINONE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009070305-A1 | METHOD OF MAKING IMIDAZOAZEPINONE COMPOUNDS | EISAI E & D MANAGEMENT CO., LTD. (JP) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065916-A1 | METHOD OF MAKING IMIDAZOAZEPINONE COMPOUNDS | CYP2C19, CYP3A7, CYP2C18 | ALDH1A1 377/4885CYP2D6 12/4885CYP3A4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.